TheraRadar
← Back
Data updated: Jul 17, 2026

HEALTHPOINT

Generics
GastroenterologyOncologyDermatology Execution: Good

HEALTHPOINT is a generic drug manufacturer focused on Gastroenterology, Oncology, Dermatology.

1976
Since
1
Drugs
-
Trials
0
New Drugs (2yr)

HEALTHPOINT at a Glance

  • Fast trial execution (16 months median completion)

HEALTHPOINT's Key Drugs

HEALTHPOINT's key approved drugs from the last 15 years (excludes generics, biosimilars and IV formulations).

No active drugs

HEALTHPOINT's Recent FDA Approvals

New NDA/BLA approvals for HEALTHPOINT over the last two years — novel drugs only, excluding generics and label supplements.

No recent approvals

HEALTHPOINT's Therapeutic Areas

HEALTHPOINT's approved drugs and pipeline span 3 therapeutic areas, led by Gastroenterology and Oncology. Weighted by commercial stage — approved drugs count most, then late-stage trials.

Gastroenterology 86%
0 drugs Phase 3: 3 Phase 2: 3 Phase 1: 7
Oncology 7%
0 drugs Phase 2: 1
Dermatology 7%
0 drugs Phase 2: 1

HEALTHPOINT's Top Competitors

HEALTHPOINT's closest competitors by therapeutic-area and drug-target overlap include Pfizer, PF PRISM CV, and Baxter. Ranked by overlap in therapeutic areas and drug targets across approved drugs and pipeline.

Pfizer big-pharma
Oncology, Dermatology
PF PRISM CV big-pharma
Oncology, Dermatology, Gastroenterology
Baxter specialty
Oncology, Dermatology
Johnson & Johnson big-pharma
Oncology, Gastroenterology
Eli Lilly big-pharma
Oncology, Dermatology

HEALTHPOINT Pipeline Snapshot

HEALTHPOINT has 15 active clinical programs from ClinicalTrials.gov — 3 Phase 3, 5 Phase 2 and 7 Phase 1.

3
Phase 3
5
Phase 2
7
Phase 1

Pro Intelligence Preview

Deep insights for investors and analysts

Revenue Insights

  • • Top drug revenue breakdown
  • • Drug-level revenue analysis

Trial Catalysts

  • • Gastroenterology pipeline focus
  • • Phase 3 readout tracking

Patent Risk

  • • Patent expiration timeline
  • • Revenue at risk analysis

Compare Companies

  • • Side-by-side pipeline analysis
  • • Revenue & market share comparison

Execution Intelligence

  • • Phase 3: 2/3 completed
  • • Speed: 16 months avg
Unlock Full Intelligence

Revenue forecasts • Trial milestones • Patent risk modeling

How We Calculate These Metrics

Execution Quality Score

Measures trial completion rates weighted by phase importance. Phase 3 trials count 4x more than Phase 1 because late-stage completion is harder and more valuable.

What counts as "completed": A trial that reached its planned endpoint and reported results. Trials that were terminated early, withdrawn, or suspended are not counted as completed—these often indicate safety issues, lack of efficacy, or strategic pivots.

  • Excellent (80%+): Top-tier execution, most trials reach planned endpoints
  • Good (60-79%): Strong execution with occasional early terminations
  • Fair (40-59%): Average execution, notable rate of terminated/withdrawn trials
  • Needs Improvement (under 40%): High termination rates, execution challenges